These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 4982302)

  • 1. The effect of calcium on behavior and drug-induced extrapyramidalism.
    Yaryura-Tobias JA; White L; Diamond B; Merlis S
    Curr Ther Res Clin Exp; 1969 Nov; 11(11):677-80. PubMed ID: 4982302
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of Parkinsonism with Tremarial (SJ-1977)].
    Kondo K; Takahashi Y; Yamamoto T; Matsumura K; Okuda Y
    No To Shinkei; 1967 Jul; 19(7):723-7. PubMed ID: 4384268
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hereditary aspects of Parkinson's disease (review of the literature)].
    Atadzhanov M
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(6):919-26. PubMed ID: 4584983
    [No Abstract]   [Full Text] [Related]  

  • 4. Irreversible drug induced parkinsonism (two case reports).
    Sahoo RN; Mitra GC; Mohanty PC
    J Assoc Physicians India; 1975 Aug; 23(8):529-30. PubMed ID: 355
    [No Abstract]   [Full Text] [Related]  

  • 5. Troxonium tosylate in drug-induced Parkinsonism: a controlled comparative study.
    Pecknold JC; Ananth JV; Ban TA; Lehmann HE
    J Clin Pharmacol New Drugs; 1971; 11(5):367-70. PubMed ID: 4998432
    [No Abstract]   [Full Text] [Related]  

  • 6. Extrapyramidal motor disorders due to toxic effect of phenothiazines.
    Tikare SK; Tikare SS
    J Indian Med Assoc; 1972 Jan; 58(2):39-42. PubMed ID: 5017799
    [No Abstract]   [Full Text] [Related]  

  • 7. [Comparative biochemical studies in organic parkinsonian syndromes and drug induced parkinsonian syndromes].
    Bruck H; Gerstenbrand F; Gnad H; Gründig E; Prosenz P
    Psychiatr Neurol (Basel); 1966; 151(2):81-7. PubMed ID: 4381177
    [No Abstract]   [Full Text] [Related]  

  • 8. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology.
    Marconi R; Lefebvre-Caparros D; Bonnet AM; Vidailhet M; Dubois B; Agid Y
    Mov Disord; 1994 Jan; 9(1):2-12. PubMed ID: 8139601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralization of extrapyramidal side-effects with Methixene.
    Maller O; Heller S
    Dis Nerv Syst; 1971 Jun; 32(6):409-15. PubMed ID: 5570695
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A; Dambrosia JM; Chase TN
    Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
    [No Abstract]   [Full Text] [Related]  

  • 11. Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
    Shoulson I
    Adv Neurol; 1983; 37():259-66. PubMed ID: 6134445
    [No Abstract]   [Full Text] [Related]  

  • 12. [Use of methamidoline in the treatment of parkinson-like manifestations due to neuroleptics].
    Arnone A; Parodi A
    Riv Sper Freniatr Med Leg Alien Ment; 1971 Dec; 95(6):1126-42. PubMed ID: 5143724
    [No Abstract]   [Full Text] [Related]  

  • 13. The antiparkinson properties of amantadine in drug-induced parkinsonism.
    Kelly JT; Abuzzahab FS
    J Clin Pharmacol New Drugs; 1971; 11(3):211-4. PubMed ID: 5211353
    [No Abstract]   [Full Text] [Related]  

  • 14. [Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease].
    Kreczy-Kleedorfer B; Wagner M; Bösch S; Poewe W
    Nervenarzt; 1993 Apr; 64(4):221-5. PubMed ID: 8506009
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of disturbances of extrapyramidal system with methixene hydrochloride].
    Kuromaru S; Funasaka K; Shuta K
    No To Shinkei; 1969 Nov; 21(11):1301-9. PubMed ID: 5394922
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drug-induced Parkinson syndrome: 10 years of drug vigilance].
    Llau ME; Nguyen L; Senard JM; Rascol O; Montastruc JL
    Therapie; 1994; 49(5):459-60. PubMed ID: 7855765
    [No Abstract]   [Full Text] [Related]  

  • 17. [Acute drug-induced extrapyramidal syndrome: case studies of a decade at the autonomous toxicology department of the Arcispedale].
    Torrini M; Masini E; Ledda F; Mannaioni PF
    Clin Ter; 1981 Jun; 97(6):561-85. PubMed ID: 7023804
    [No Abstract]   [Full Text] [Related]  

  • 18. L-DOPA therapy in drug-induced parkinsonism evaluated by the method measuring the facial expression.
    Kimura N; Tsukue I
    Hiroshima J Med Sci; 1971 Mar; 20(1):55-63. PubMed ID: 5121129
    [No Abstract]   [Full Text] [Related]  

  • 19. Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease.
    Birkmayer W; Riederer P
    Adv Neurol; 1984; 40():475-81. PubMed ID: 6421111
    [No Abstract]   [Full Text] [Related]  

  • 20. An evaluation of the permanence of the "tardive dyskinesias".
    Paulson GW
    Dis Nerv Syst; 1968 Oct; 29(10):692-4. PubMed ID: 5717285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.